Sevastianov V.I.,Shumakov Federal Research Center for Transplantology and Artificial Organs |
Dukhina G.A.,Institute of Biomedical Research and Technology |
Ponomareva A.S.,Shumakov Federal Research Center for Transplantology and Artificial Organs |
Kirsanova L.A.,Shumakov Federal Research Center for Transplantology and Artificial Organs |
And 2 more authors.
Inorganic Materials: Applied Research | Year: 2015
An in vivo study of the biological safety of a biomedical cell product for regeneration of articular cartilage with subcutaneous implantation of cell-engineered cartilage tissue was carried out. A comparative study of the biological safety of the cell-engineered construct of human articular cartilage tissue (CEC hAT) and the biocompatible BMCH matrix in an implantation test did not show significant differences between the control and experimental groups. The results demonstrated that the cell component of the cell-engineered construct of hAT is not a risk factor for its implantation for up to 28 days. During the study, some signs of formation of articular tissue were observed at the site of subcutaneous implantation of the CEC hAT. Considering high proliferation and differentiation activity of the CEC hAT previously confirmed after its cultivation for 42 days, it is possible to suggest the potential of using CEC hAT for regeneration of injured cartilage as an injection form of biomedical cell product. © 2015, Pleiades Publishing, Ltd. Source